SlideShare une entreprise Scribd logo
1  sur  28
DTEC        ™


IMPROVING THE QUALITY OF
CARE THROUGH CLAIMS DATA
ANALYSIS
Benjamin Eng, MD, MA

AHQA 2005 Fall Meeting
Quality Measurement and
Improvement in the New
Medicare Prescription Drug
Benefit
November 17, 2005
Washington, D.C.
AGENDA

     s Introduction

     s What is DTEC™?

     s DTEC™ Reports

     s Examples from test sites

     s Potential Part D implications and applications




© Pfizer Inc. All rights reserved
CHALLENGES FACING
   HEALTHCARE TODAY




          Many Organizations Face Challenges in
            Identifying Gaps in the Quality of
               Care for Patient Populations




© Pfizer Inc. All rights reserved
™
DTEC Supports the Quality Improvement Process
                               Assess Baseline
                                Performance


                              Identify Barriers for
                                 Intervention


                             Target Individuals for
                                 Intervention


                             Design and Implement
                                  Intervention


                            Reassess Performance
                                 Periodically


© Pfizer Inc. All rights reserved
™
DTEC Supports the Quality Improvement Process
                               Assess Baseline
                                Performance


                              Identify Barriers for
                                 Intervention


                             Target Individuals for
                                 Intervention


                             Design and Implement
                                  Intervention


                            Reassess Performance
                                 Periodically


© Pfizer Inc. All rights reserved
WHAT IS DTEC™?

   s DTEC is a service offered by Pfizer that:
       • Uses the customer’s claims data to identify their member populations
         with targeted diseases

          – First module covers CV diseases (hyperlipidemia, hypertension,
            diabetes, ischemic heart disease, congestive heart failure)

       • Produces aggregate and member-specific reports

       • Provides analysis of the aggregate reports

   s DTEC is HIPAA-compliant because no member-specific data
      leaves the customer or is viewed by Pfizer




© Pfizer Inc. All rights reserved
DTEC™ BENEFITS

   s DTEC
       • Lowers the barriers to improving the quality of care members receive

       • Leverages existing data resources to develop reports that facilitate use
         of appropriate interventions for targeted groups of members




© Pfizer Inc. All rights reserved
DATA FIELDS UTILIZED BY DTEC™ SOFTWARE
Professional Services Information               Drug Utilization Information

 s   Member ID                                  s   NDC Number
 s   Claim Number                               s   Member ID
 s   Claim Line Number                          s   Prescription ID
 s   From Service Date                          s   Date Filled
 s   To Service Date                            s   Days Supplied
 s   Procedure Code                             s   Quantity
 s   Principal Diagnosis            Analyzed
 s   Additional Diagnoses (4)       Over Time
 s   Place of Service




        Enrollment Information                  Facility Services Information

 s   Member ID                                  s   Member ID
 s   PCP ID                                     s   Claim Number
 s   Member Gender                              s   Claim Line Number
 s   Year of Birth                              s   From Date
                                                                         EMERGENCY




 s   Effective Date                             s   To Date
 s   Termination Date                           s   Principal Diagnosis
                                                s   Additional Diagnoses (4)
                                                s   Place of Service


© Pfizer Inc. All rights reserved
DTEC™ SUMMARY DATABASE
                         Claims and Enrollment Data
                             Data for Population
                                   (4 files)



                           Continuous Enrollment
         DTEC Software




                           Disease Identification
                                                      Summary Dataset
                                                      s Demographics
                              Demographics
                                                      s Patterns
                              Co-morbidities
                              Complications           s Care Improvement
                                Utilization


                               Quality Gaps


© Pfizer Inc. All rights reserved
DTEC™ PATIENT IDENTIFICATION

   s Levels of confidence for identifying members with each
      targeted disease
       • Lenient, Normal and Strict

   s Stratifications of disease severity
       • Usual, Moderate and High




© Pfizer Inc. All rights reserved
CONFIDENCE LEVELS FOR DISEASE
   IDENTIFICATION ARE INCLUSIVE
   (LENIENT INCLUDES MEMBERS CATEGORIZED AS NORMAL AND STRICT)




                 Lenient        Normal   Strict




© Pfizer Inc. All rights reserved
EXAMPLE:
   DTEC™ CRITERIA FOR IDENTIFYING
   MEMBERS WITH HYPERLIPIDEMIA
                                       Minimum Number of Claims Needed
  Criteria                               Lenient    Normal     Strict

  Hospitalization with Diagnosis or         1          1         1
  Diagnosis on Professional Claims
  with Different Dates of Service or        1          3         4
  Rx for Lipid Lowering Agent or            1          2         4
  Diagnosis on Professional Claims
  and Rx for Lipid Lowering Agent          NA         1/1        3/1




© Pfizer Inc. All rights reserved
PERCENT OF MEMBERS IN COMMERCIAL HEALTH
   PLAN POPULATION IDENTIFIED BY DTEC™ AS
   HAVING CV DISEASE
                                                                           25%



                                              16%
                               14%


                  5%
                                                           4%



                 DM         Hyperlipid        HTN          IHD         Any CVDs

                          Lenient             Normal              Strict
   Data on file for 100,000 member commercial health plan
   Note: The Lenient category includes members classified as Normal and Strict

© Pfizer Inc. All rights reserved
DTEC™ SOFTWARE PROCESS
                                    Raw Claims Data
                                       (4 Files)


                                   DTEC Phase 1
                              Data Audit and Summary


                            Summary Access Database
                                  (in DTEC)


                                     DTEC Phase 2
                                    Query Database


   Demographic            Utilization            Clinical   Care Improvement
     Reports               Reports               Reports         Reports

                                                                Patient
                                                               Drill Down


© Pfizer Inc. All rights reserved
DTEC™ REPORTS
                                       DTEC Reports                        CHF
                                                                          Added
                       Summary Report




    Hypertension        Hyperlipidemia          Ischemic Heart          Diabetes
                                                    Disease


     6 Reports             6 Reports                  6 Reports         6 Reports


 1 Care Imp. Report    1 Care Imp. Report      1 Care Imp. Report   1 Care Imp. Report




© Pfizer Inc. All rights reserved
DTEC™ AGGREGATE DISEASE
   POPULATION REPORTS
   s Disease prevalence by level of confidence

   s Demographics by disease severity

   s Comorbidities and complications (2 reports)

   s Hospitalizations, ER visits and medical services received

   s Medications / medication compliance (2 reports)

   s Care Improvement reports




© Pfizer Inc. All rights reserved
CARE IMPROVEMENT REPORTS

  DTEC™ uses specific predefined criteria, called
  care improvement algorithms, that identify populations
  with opportunities to improve the quality of care
   s Aggregate reports show the percentage of the disease
      population meeting the care improvement algorithm criteria
   s Member specific targeting reports “drill down” and produce
      lists of individual members for possible intervention




© Pfizer Inc. All rights reserved
Sample Claims Based Quality Inferences
            Heart Failure                       Diabetes


   s No renal function testing       s No HbA1c test

   s No lipid profile                s No lipid profile

   s No cholesterol test after       s No renal function testing
      hospitalization
                                     s No urine protein test
   s Thiazide or loop diuretic, no
                                     s No eye examination
      potassium check
                                     s No follow up visit within 45
   s ACE or ARB treatment
                                       days of hospitalization
   s No follow up visit within 45
                                     s Fewer than 2 visits during
      days of discharge
                                       reporting period




© Pfizer Inc. All rights reserved
Intervention Decision Making Belongs in the
  Hands of the Clinician
                                           DTEC Reports                          CHF
                                                                                Added
                           Summary Report




    Hypertension            Hyperlipidemia            Ischemic Heart           Diabetes
                                                          Disease


     6 Reports                 6 Reports                  6 Reports           6 Reports


 1 Care Imp. Report        1 Care Imp. Report       1 Care Imp. Report    1 Care Imp. Report


 1 Patient CI Report       1 Patient CI Report      1 Patient CI Report   1 Patient CI Report


                                       Patient Detail Report

   CI – Care Improvement
© Pfizer Inc. All rights reserved
EXAMPLES OF DTEC™
                                    DATA SUMMARIES
                                    FROM THE TEST SITES




© Pfizer Inc. All rights reserved
PREVALENCE OF CARDIOVASCULAR DISEASES
   COMPARED TO BENCHMARK DATA
   Percent of Members with CVD
                                         35%




                                  16%                 16% 15%
             10%
                     4%                                                     5%
                                                                                   3%


                 DM              Hyperlipid               HTN                  IHD

                                 MCO            Benchmark (NHANES III)
   Data on file for 200,000 member combined commercial and Medicare health plans

© Pfizer Inc. All rights reserved
CLASSIFICATION OF MEMBERS WITH
   DIABETES BY SEVERITY (N=5,629)




              Usual             44%                      43%             Moderate




                                             13%



                                    Severe

   Data on file for 200,000 member combined commercial and Medicare health plans

© Pfizer Inc. All rights reserved
DIABETES COMORBIDITIES
   Percent of Members with Diabetes

                        51%



            36%


                                    22%


                                                11%        11%

                                                                        4%           3%

       Hyperlipidemia           Ischemic HD         Cerebrovascular Dis            Acute MI
                    Hypertension                CHF                   Obesity


   Data on file for 200,000 member combined commercial and Medicare health plans

© Pfizer Inc. All rights reserved
COMPLICATIONS IN MEMBERS
   WITH DIABETES
   Percent of Members
                                                                        15%



                                                10%

                         8%
                                                                                      7%


                                                            3%
             1%                      1%


       Hypoglycemia Kidney          Skin        UTI        Visual      Other       Peripheral
                    Failure         Ulcer                   Loss        Eye        Neuropathy



   Data on file for 200,000 member combined commercial and Medicare health plans

© Pfizer Inc. All rights reserved
CARE IMPROVEMENT OPPORTUNITIES IN
   MEMBERS WITH DIABETES
   Percent of Members
                        41%



                                    29%                                              28%
                                                23%


            12%                                                          13%
                                                            9%




           No HbA1c    No Eye      No Lipid   w/HTN,      w/↑Chol,    No Hosp F/U   <2 Visits/
                        Exam        Profile   No ACEI     No Statin                   Year
                                               or βB

   Data on file for 200,000 member combined commercial and Medicare health plans

© Pfizer Inc. All rights reserved
EXPERIENCE WITH DTEC™ SERVICE
  s Implemented with nearly 20 health plans
      • Includes 2 Medicare Advantage plans

  s Purpose of DTEC implementation has included
      • To measure baseline CV assessment data

      • To determine whether to start a CV quality initiative

      • To identify patients for a  case management quality improvement
        program
      • To identify patients for a pilot Diabetes intervention program     

      • To identify patients for a patient CV education program

      • To document quality trends over multiple years

      • To identify a population of high risk patients to conduct an
        adherence study on
© Pfizer Inc. All rights reserved
Unique Features of DTEC’s Design
   s Data audit and integration is automated after data input
      files are properly formatted
   s Summary dataset is retained while individual claims are
      processed and discarded
   s Pre-defined reports are based on the summary dataset,
      transferring analysis to the desktop
   s Population level reporting is linked to member level drill
      down reports for targeting interventions
   s Clinician level review of drill down patient lists is
      supported to verify quality improvement insights




© Pfizer Inc. All rights reserved
Possible Implications for QIOs and
   Medicare Part D Quality
   s Claims data can provide insight into the quality of care for
      beneficiaries
   s The resource burden to integrate and analyze A, B, D and
      administrative claims data can be dramatically lowered
      leveraging this type of technology
   s Similar tools can place analytic power and targeting
      capabilities in the hands of Quality Improvement
      Organizations to work with Medicare providers
   s Data analytics can only support clinical decision making.
      Clinical decision making belongs in the hands of the
      clinician.




© Pfizer Inc. All rights reserved

Contenu connexe

En vedette

България Радослав-Севим 10 д 2011- пги
България Радослав-Севим 10 д 2011- пгиБългария Радослав-Севим 10 д 2011- пги
България Радослав-Севим 10 д 2011- пгиAdelina Peneva - Club "History"
 
D K R Colorado B I O 07 Final
D K R  Colorado  B I O 07  FinalD K R  Colorado  B I O 07  Final
D K R Colorado B I O 07 FinalThink Science Now
 
Нашият Клуб "Историческа лаборатория", ПГИ - гр. Шумен
Нашият Клуб "Историческа лаборатория", ПГИ - гр. ШуменНашият Клуб "Историческа лаборатория", ПГИ - гр. Шумен
Нашият Клуб "Историческа лаборатория", ПГИ - гр. ШуменAdelina Peneva - Club "History"
 
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-Шумен
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-ШуменВ РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-Шумен
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-ШуменAdelina Peneva - Club "History"
 
Панагюрското златно съкровище
Панагюрското златно съкровищеПанагюрското златно съкровище
Панагюрското златно съкровищеAdelina Peneva - Club "History"
 
Монети - Бейхан Данъджъ 11 Б - ПГИ
Монети - Бейхан Данъджъ 11 Б - ПГИМонети - Бейхан Данъджъ 11 Б - ПГИ
Монети - Бейхан Данъджъ 11 Б - ПГИAdelina Peneva - Club "History"
 
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - Шумен
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - ШуменОрганизация и анализ на данни. Бейхан Данаджъ-ПГИ - Шумен
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - ШуменAdelina Peneva - Club "History"
 
историческа лаборатория патронен празник пги-шумен 2013 анимация
историческа лаборатория патронен празник пги-шумен  2013 анимацияисторическа лаборатория патронен празник пги-шумен  2013 анимация
историческа лаборатория патронен празник пги-шумен 2013 анимацияAdelina Peneva - Club "History"
 
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...Adelina Peneva - Club "History"
 
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...Adelina Peneva - Club "History"
 

En vedette (16)

ПГИ-Шумен Патронен празник
ПГИ-Шумен Патронен празникПГИ-Шумен Патронен празник
ПГИ-Шумен Патронен празник
 
България Радослав-Севим 10 д 2011- пги
България Радослав-Севим 10 д 2011- пгиБългария Радослав-Севим 10 д 2011- пги
България Радослав-Севим 10 д 2011- пги
 
D K R Colorado B I O 07 Final
D K R  Colorado  B I O 07  FinalD K R  Colorado  B I O 07  Final
D K R Colorado B I O 07 Final
 
Ediz 9v n9-homework-lesson 16-amerika za amerikantsite
Ediz 9v n9-homework-lesson 16-amerika za amerikantsiteEdiz 9v n9-homework-lesson 16-amerika za amerikantsite
Ediz 9v n9-homework-lesson 16-amerika za amerikantsite
 
Нашият Клуб "Историческа лаборатория", ПГИ - гр. Шумен
Нашият Клуб "Историческа лаборатория", ПГИ - гр. ШуменНашият Клуб "Историческа лаборатория", ПГИ - гр. Шумен
Нашият Клуб "Историческа лаборатория", ПГИ - гр. Шумен
 
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-Шумен
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-ШуменВ РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-Шумен
В РИМ-Шумен. Клуб "Историческа лаборатория", ПГ по икономика-Шумен
 
Панагюрското златно съкровище
Панагюрското златно съкровищеПанагюрското златно съкровище
Панагюрското златно съкровище
 
Getman Apr29 F I N A L
Getman  Apr29  F I N A LGetman  Apr29  F I N A L
Getman Apr29 F I N A L
 
1 ww
1 ww1 ww
1 ww
 
Монети - Бейхан Данъджъ 11 Б - ПГИ
Монети - Бейхан Данъджъ 11 Б - ПГИМонети - Бейхан Данъджъ 11 Б - ПГИ
Монети - Бейхан Данъджъ 11 Б - ПГИ
 
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - Шумен
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - ШуменОрганизация и анализ на данни. Бейхан Данаджъ-ПГИ - Шумен
Организация и анализ на данни. Бейхан Данаджъ-ПГИ - Шумен
 
04 Miller
04 Miller04 Miller
04 Miller
 
историческа лаборатория патронен празник пги-шумен 2013 анимация
историческа лаборатория патронен празник пги-шумен  2013 анимацияисторическа лаборатория патронен празник пги-шумен  2013 анимация
историческа лаборатория патронен празник пги-шумен 2013 анимация
 
япония
японияяпония
япония
 
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...
Клуб "Историческа лаборатория", ПГИ - гр. Шумен - Старият град Шумен - Зехра ...
 
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...
ПГИ-Шумен. Клуб "Историческа лаборатория"-Малките екскурзоводи в Нощта на муз...
 

Similaire à Eng

Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...
Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...
Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...Health IT Conference – iHT2
 
Emerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementEmerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementArshad Mohammed
 
What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...3GDR
 
Clinical information system presentation
Clinical information system presentationClinical information system presentation
Clinical information system presentationbooob112
 
Diagnotes open app challenge - phase 1 submission
Diagnotes   open app challenge - phase 1 submissionDiagnotes   open app challenge - phase 1 submission
Diagnotes open app challenge - phase 1 submissionDiagnotes
 
Companion Diagnostics in a Minute
Companion Diagnostics in a MinuteCompanion Diagnostics in a Minute
Companion Diagnostics in a MinuteLisa Brown
 
Elite Capabilities Hit
Elite Capabilities HitElite Capabilities Hit
Elite Capabilities Hitelitetechnical
 
Understanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationUnderstanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationEmily Kunka, MS, CCRP
 
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...Health IT Conference – iHT2
 
Semantic Technology for Provider-Payer-Pharma Data Collaboration
Semantic Technology for Provider-Payer-Pharma Data CollaborationSemantic Technology for Provider-Payer-Pharma Data Collaboration
Semantic Technology for Provider-Payer-Pharma Data CollaborationThomas Kelly, PMP
 
Insource Healthcare Solutions
Insource Healthcare SolutionsInsource Healthcare Solutions
Insource Healthcare Solutionsmmarsocci
 
Open app challenge phase 1 submission team recommind
Open app challenge   phase 1 submission team recommindOpen app challenge   phase 1 submission team recommind
Open app challenge phase 1 submission team recommindKathleenAller
 
What you should know about Meaningful Use
What you should know about Meaningful UseWhat you should know about Meaningful Use
What you should know about Meaningful Usedelmore44
 
Meaningful Use Sequest
Meaningful Use SequestMeaningful Use Sequest
Meaningful Use Sequestnmitra77
 
L2 Using Information Technology
L2 Using Information TechnologyL2 Using Information Technology
L2 Using Information Technologyprimary
 
Pentaho Healthcare Solutions
Pentaho Healthcare SolutionsPentaho Healthcare Solutions
Pentaho Healthcare SolutionsPentaho
 
Insights into the Canadian eHealth Landscape - MaRS Future of Medicine
Insights into the Canadian eHealth Landscape - MaRS Future of MedicineInsights into the Canadian eHealth Landscape - MaRS Future of Medicine
Insights into the Canadian eHealth Landscape - MaRS Future of MedicineMaRS Discovery District
 

Similaire à Eng (20)

Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...
Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...
Case Study “Business Intelligence: Supporting Delivery of High Quality Care a...
 
Emerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementEmerging Trends in Clinical Data Management
Emerging Trends in Clinical Data Management
 
What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...
 
Platform Adoption
Platform AdoptionPlatform Adoption
Platform Adoption
 
Clinical information system presentation
Clinical information system presentationClinical information system presentation
Clinical information system presentation
 
Diagnotes open app challenge - phase 1 submission
Diagnotes   open app challenge - phase 1 submissionDiagnotes   open app challenge - phase 1 submission
Diagnotes open app challenge - phase 1 submission
 
Companion Diagnostics in a Minute
Companion Diagnostics in a MinuteCompanion Diagnostics in a Minute
Companion Diagnostics in a Minute
 
Elite Capabilities Hit
Elite Capabilities HitElite Capabilities Hit
Elite Capabilities Hit
 
Understanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into ImaginationUnderstanding Digital Therapeutics: Journey into Imagination
Understanding Digital Therapeutics: Journey into Imagination
 
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...
iHT2 Health IT Summit San Francisco 2013 - Davin Lundquist, MD, CMIO, Dignity...
 
Semantic Technology for Provider-Payer-Pharma Data Collaboration
Semantic Technology for Provider-Payer-Pharma Data CollaborationSemantic Technology for Provider-Payer-Pharma Data Collaboration
Semantic Technology for Provider-Payer-Pharma Data Collaboration
 
Insource Healthcare Solutions
Insource Healthcare SolutionsInsource Healthcare Solutions
Insource Healthcare Solutions
 
Open app challenge phase 1 submission team recommind
Open app challenge   phase 1 submission team recommindOpen app challenge   phase 1 submission team recommind
Open app challenge phase 1 submission team recommind
 
Clinical Psychology Internships Training
Clinical Psychology Internships TrainingClinical Psychology Internships Training
Clinical Psychology Internships Training
 
What you should know about Meaningful Use
What you should know about Meaningful UseWhat you should know about Meaningful Use
What you should know about Meaningful Use
 
Meaningful Use Sequest
Meaningful Use SequestMeaningful Use Sequest
Meaningful Use Sequest
 
L2 Using Information Technology
L2 Using Information TechnologyL2 Using Information Technology
L2 Using Information Technology
 
Pentaho Healthcare Solutions
Pentaho Healthcare SolutionsPentaho Healthcare Solutions
Pentaho Healthcare Solutions
 
Insights into the Canadian eHealth Landscape - MaRS Future of Medicine
Insights into the Canadian eHealth Landscape - MaRS Future of MedicineInsights into the Canadian eHealth Landscape - MaRS Future of Medicine
Insights into the Canadian eHealth Landscape - MaRS Future of Medicine
 
MED dra Coding -MSSO
MED dra Coding -MSSOMED dra Coding -MSSO
MED dra Coding -MSSO
 

Dernier

Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfHyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfPrecisely
 
DevoxxFR 2024 Reproducible Builds with Apache Maven
DevoxxFR 2024 Reproducible Builds with Apache MavenDevoxxFR 2024 Reproducible Builds with Apache Maven
DevoxxFR 2024 Reproducible Builds with Apache MavenHervé Boutemy
 
Moving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfMoving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfLoriGlavin3
 
What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024Stephanie Beckett
 
Advanced Computer Architecture – An Introduction
Advanced Computer Architecture – An IntroductionAdvanced Computer Architecture – An Introduction
Advanced Computer Architecture – An IntroductionDilum Bandara
 
Scanning the Internet for External Cloud Exposures via SSL Certs
Scanning the Internet for External Cloud Exposures via SSL CertsScanning the Internet for External Cloud Exposures via SSL Certs
Scanning the Internet for External Cloud Exposures via SSL CertsRizwan Syed
 
"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii SoldatenkoFwdays
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxLoriGlavin3
 
Dev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebDev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebUiPathCommunity
 
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024BookNet Canada
 
What is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfWhat is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfMounikaPolabathina
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity PlanDatabarracks
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.Curtis Poe
 
Nell’iperspazio con Rocket: il Framework Web di Rust!
Nell’iperspazio con Rocket: il Framework Web di Rust!Nell’iperspazio con Rocket: il Framework Web di Rust!
Nell’iperspazio con Rocket: il Framework Web di Rust!Commit University
 
Commit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyCommit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyAlfredo García Lavilla
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Mark Simos
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024BookNet Canada
 
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxLoriGlavin3
 
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024BookNet Canada
 
Connect Wave/ connectwave Pitch Deck Presentation
Connect Wave/ connectwave Pitch Deck PresentationConnect Wave/ connectwave Pitch Deck Presentation
Connect Wave/ connectwave Pitch Deck PresentationSlibray Presentation
 

Dernier (20)

Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdfHyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
Hyperautomation and AI/ML: A Strategy for Digital Transformation Success.pdf
 
DevoxxFR 2024 Reproducible Builds with Apache Maven
DevoxxFR 2024 Reproducible Builds with Apache MavenDevoxxFR 2024 Reproducible Builds with Apache Maven
DevoxxFR 2024 Reproducible Builds with Apache Maven
 
Moving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdfMoving Beyond Passwords: FIDO Paris Seminar.pdf
Moving Beyond Passwords: FIDO Paris Seminar.pdf
 
What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024What's New in Teams Calling, Meetings and Devices March 2024
What's New in Teams Calling, Meetings and Devices March 2024
 
Advanced Computer Architecture – An Introduction
Advanced Computer Architecture – An IntroductionAdvanced Computer Architecture – An Introduction
Advanced Computer Architecture – An Introduction
 
Scanning the Internet for External Cloud Exposures via SSL Certs
Scanning the Internet for External Cloud Exposures via SSL CertsScanning the Internet for External Cloud Exposures via SSL Certs
Scanning the Internet for External Cloud Exposures via SSL Certs
 
"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko"Debugging python applications inside k8s environment", Andrii Soldatenko
"Debugging python applications inside k8s environment", Andrii Soldatenko
 
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptxDigital Identity is Under Attack: FIDO Paris Seminar.pptx
Digital Identity is Under Attack: FIDO Paris Seminar.pptx
 
Dev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio WebDev Dives: Streamline document processing with UiPath Studio Web
Dev Dives: Streamline document processing with UiPath Studio Web
 
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
 
What is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdfWhat is DBT - The Ultimate Data Build Tool.pdf
What is DBT - The Ultimate Data Build Tool.pdf
 
How to write a Business Continuity Plan
How to write a Business Continuity PlanHow to write a Business Continuity Plan
How to write a Business Continuity Plan
 
How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.How AI, OpenAI, and ChatGPT impact business and software.
How AI, OpenAI, and ChatGPT impact business and software.
 
Nell’iperspazio con Rocket: il Framework Web di Rust!
Nell’iperspazio con Rocket: il Framework Web di Rust!Nell’iperspazio con Rocket: il Framework Web di Rust!
Nell’iperspazio con Rocket: il Framework Web di Rust!
 
Commit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easyCommit 2024 - Secret Management made easy
Commit 2024 - Secret Management made easy
 
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
Tampa BSides - Chef's Tour of Microsoft Security Adoption Framework (SAF)
 
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
Transcript: New from BookNet Canada for 2024: Loan Stars - Tech Forum 2024
 
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptxThe Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
The Fit for Passkeys for Employee and Consumer Sign-ins: FIDO Paris Seminar.pptx
 
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
New from BookNet Canada for 2024: BNC CataList - Tech Forum 2024
 
Connect Wave/ connectwave Pitch Deck Presentation
Connect Wave/ connectwave Pitch Deck PresentationConnect Wave/ connectwave Pitch Deck Presentation
Connect Wave/ connectwave Pitch Deck Presentation
 

Eng

  • 1. DTEC ™ IMPROVING THE QUALITY OF CARE THROUGH CLAIMS DATA ANALYSIS Benjamin Eng, MD, MA AHQA 2005 Fall Meeting Quality Measurement and Improvement in the New Medicare Prescription Drug Benefit November 17, 2005 Washington, D.C.
  • 2. AGENDA s Introduction s What is DTEC™? s DTEC™ Reports s Examples from test sites s Potential Part D implications and applications © Pfizer Inc. All rights reserved
  • 3. CHALLENGES FACING HEALTHCARE TODAY Many Organizations Face Challenges in Identifying Gaps in the Quality of Care for Patient Populations © Pfizer Inc. All rights reserved
  • 4. ™ DTEC Supports the Quality Improvement Process Assess Baseline Performance Identify Barriers for Intervention Target Individuals for Intervention Design and Implement Intervention Reassess Performance Periodically © Pfizer Inc. All rights reserved
  • 5. ™ DTEC Supports the Quality Improvement Process Assess Baseline Performance Identify Barriers for Intervention Target Individuals for Intervention Design and Implement Intervention Reassess Performance Periodically © Pfizer Inc. All rights reserved
  • 6. WHAT IS DTEC™? s DTEC is a service offered by Pfizer that: • Uses the customer’s claims data to identify their member populations with targeted diseases – First module covers CV diseases (hyperlipidemia, hypertension, diabetes, ischemic heart disease, congestive heart failure) • Produces aggregate and member-specific reports • Provides analysis of the aggregate reports s DTEC is HIPAA-compliant because no member-specific data leaves the customer or is viewed by Pfizer © Pfizer Inc. All rights reserved
  • 7. DTEC™ BENEFITS s DTEC • Lowers the barriers to improving the quality of care members receive • Leverages existing data resources to develop reports that facilitate use of appropriate interventions for targeted groups of members © Pfizer Inc. All rights reserved
  • 8. DATA FIELDS UTILIZED BY DTEC™ SOFTWARE Professional Services Information Drug Utilization Information s Member ID s NDC Number s Claim Number s Member ID s Claim Line Number s Prescription ID s From Service Date s Date Filled s To Service Date s Days Supplied s Procedure Code s Quantity s Principal Diagnosis Analyzed s Additional Diagnoses (4) Over Time s Place of Service Enrollment Information Facility Services Information s Member ID s Member ID s PCP ID s Claim Number s Member Gender s Claim Line Number s Year of Birth s From Date EMERGENCY s Effective Date s To Date s Termination Date s Principal Diagnosis s Additional Diagnoses (4) s Place of Service © Pfizer Inc. All rights reserved
  • 9. DTEC™ SUMMARY DATABASE Claims and Enrollment Data Data for Population (4 files) Continuous Enrollment DTEC Software Disease Identification Summary Dataset s Demographics Demographics s Patterns Co-morbidities Complications s Care Improvement Utilization Quality Gaps © Pfizer Inc. All rights reserved
  • 10. DTEC™ PATIENT IDENTIFICATION s Levels of confidence for identifying members with each targeted disease • Lenient, Normal and Strict s Stratifications of disease severity • Usual, Moderate and High © Pfizer Inc. All rights reserved
  • 11. CONFIDENCE LEVELS FOR DISEASE IDENTIFICATION ARE INCLUSIVE (LENIENT INCLUDES MEMBERS CATEGORIZED AS NORMAL AND STRICT) Lenient Normal Strict © Pfizer Inc. All rights reserved
  • 12. EXAMPLE: DTEC™ CRITERIA FOR IDENTIFYING MEMBERS WITH HYPERLIPIDEMIA Minimum Number of Claims Needed Criteria Lenient Normal Strict Hospitalization with Diagnosis or 1 1 1 Diagnosis on Professional Claims with Different Dates of Service or 1 3 4 Rx for Lipid Lowering Agent or 1 2 4 Diagnosis on Professional Claims and Rx for Lipid Lowering Agent NA 1/1 3/1 © Pfizer Inc. All rights reserved
  • 13. PERCENT OF MEMBERS IN COMMERCIAL HEALTH PLAN POPULATION IDENTIFIED BY DTEC™ AS HAVING CV DISEASE 25% 16% 14% 5% 4% DM Hyperlipid HTN IHD Any CVDs Lenient Normal Strict Data on file for 100,000 member commercial health plan Note: The Lenient category includes members classified as Normal and Strict © Pfizer Inc. All rights reserved
  • 14. DTEC™ SOFTWARE PROCESS Raw Claims Data (4 Files) DTEC Phase 1 Data Audit and Summary Summary Access Database (in DTEC) DTEC Phase 2 Query Database Demographic Utilization Clinical Care Improvement Reports Reports Reports Reports Patient Drill Down © Pfizer Inc. All rights reserved
  • 15. DTEC™ REPORTS DTEC Reports CHF Added Summary Report Hypertension Hyperlipidemia Ischemic Heart Diabetes Disease 6 Reports 6 Reports 6 Reports 6 Reports 1 Care Imp. Report 1 Care Imp. Report 1 Care Imp. Report 1 Care Imp. Report © Pfizer Inc. All rights reserved
  • 16. DTEC™ AGGREGATE DISEASE POPULATION REPORTS s Disease prevalence by level of confidence s Demographics by disease severity s Comorbidities and complications (2 reports) s Hospitalizations, ER visits and medical services received s Medications / medication compliance (2 reports) s Care Improvement reports © Pfizer Inc. All rights reserved
  • 17. CARE IMPROVEMENT REPORTS DTEC™ uses specific predefined criteria, called care improvement algorithms, that identify populations with opportunities to improve the quality of care s Aggregate reports show the percentage of the disease population meeting the care improvement algorithm criteria s Member specific targeting reports “drill down” and produce lists of individual members for possible intervention © Pfizer Inc. All rights reserved
  • 18. Sample Claims Based Quality Inferences Heart Failure Diabetes s No renal function testing s No HbA1c test s No lipid profile s No lipid profile s No cholesterol test after s No renal function testing hospitalization s No urine protein test s Thiazide or loop diuretic, no s No eye examination potassium check s No follow up visit within 45 s ACE or ARB treatment days of hospitalization s No follow up visit within 45 s Fewer than 2 visits during days of discharge reporting period © Pfizer Inc. All rights reserved
  • 19. Intervention Decision Making Belongs in the Hands of the Clinician DTEC Reports CHF Added Summary Report Hypertension Hyperlipidemia Ischemic Heart Diabetes Disease 6 Reports 6 Reports 6 Reports 6 Reports 1 Care Imp. Report 1 Care Imp. Report 1 Care Imp. Report 1 Care Imp. Report 1 Patient CI Report 1 Patient CI Report 1 Patient CI Report 1 Patient CI Report Patient Detail Report CI – Care Improvement © Pfizer Inc. All rights reserved
  • 20. EXAMPLES OF DTEC™ DATA SUMMARIES FROM THE TEST SITES © Pfizer Inc. All rights reserved
  • 21. PREVALENCE OF CARDIOVASCULAR DISEASES COMPARED TO BENCHMARK DATA Percent of Members with CVD 35% 16% 16% 15% 10% 4% 5% 3% DM Hyperlipid HTN IHD MCO Benchmark (NHANES III) Data on file for 200,000 member combined commercial and Medicare health plans © Pfizer Inc. All rights reserved
  • 22. CLASSIFICATION OF MEMBERS WITH DIABETES BY SEVERITY (N=5,629) Usual 44% 43% Moderate 13% Severe Data on file for 200,000 member combined commercial and Medicare health plans © Pfizer Inc. All rights reserved
  • 23. DIABETES COMORBIDITIES Percent of Members with Diabetes 51% 36% 22% 11% 11% 4% 3% Hyperlipidemia Ischemic HD Cerebrovascular Dis Acute MI Hypertension CHF Obesity Data on file for 200,000 member combined commercial and Medicare health plans © Pfizer Inc. All rights reserved
  • 24. COMPLICATIONS IN MEMBERS WITH DIABETES Percent of Members 15% 10% 8% 7% 3% 1% 1% Hypoglycemia Kidney Skin UTI Visual Other Peripheral Failure Ulcer Loss Eye Neuropathy Data on file for 200,000 member combined commercial and Medicare health plans © Pfizer Inc. All rights reserved
  • 25. CARE IMPROVEMENT OPPORTUNITIES IN MEMBERS WITH DIABETES Percent of Members 41% 29% 28% 23% 12% 13% 9% No HbA1c No Eye No Lipid w/HTN, w/↑Chol, No Hosp F/U <2 Visits/ Exam Profile No ACEI No Statin Year or βB Data on file for 200,000 member combined commercial and Medicare health plans © Pfizer Inc. All rights reserved
  • 26. EXPERIENCE WITH DTEC™ SERVICE s Implemented with nearly 20 health plans • Includes 2 Medicare Advantage plans s Purpose of DTEC implementation has included • To measure baseline CV assessment data • To determine whether to start a CV quality initiative • To identify patients for a  case management quality improvement program • To identify patients for a pilot Diabetes intervention program      • To identify patients for a patient CV education program • To document quality trends over multiple years • To identify a population of high risk patients to conduct an adherence study on © Pfizer Inc. All rights reserved
  • 27. Unique Features of DTEC’s Design s Data audit and integration is automated after data input files are properly formatted s Summary dataset is retained while individual claims are processed and discarded s Pre-defined reports are based on the summary dataset, transferring analysis to the desktop s Population level reporting is linked to member level drill down reports for targeting interventions s Clinician level review of drill down patient lists is supported to verify quality improvement insights © Pfizer Inc. All rights reserved
  • 28. Possible Implications for QIOs and Medicare Part D Quality s Claims data can provide insight into the quality of care for beneficiaries s The resource burden to integrate and analyze A, B, D and administrative claims data can be dramatically lowered leveraging this type of technology s Similar tools can place analytic power and targeting capabilities in the hands of Quality Improvement Organizations to work with Medicare providers s Data analytics can only support clinical decision making. Clinical decision making belongs in the hands of the clinician. © Pfizer Inc. All rights reserved